Imperial Innovations

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Resolver is an independent online resolution service that connects consumers directly with businesses to address customer service issues efficiently. The platform facilitates communication and provides a streamlined process for resolving disputes, ensuring that consumers can effectively voice their concerns while businesses can retain their customers. Resolver offers a fully online, end-to-end arbitration and dispute resolution system, which is both fast and cost-effective. Additionally, the platform delivers value-added services to businesses by enhancing the issue-resolution process and providing real-time consumer feedback insights through advanced AI technology. This comprehensive approach allows consumers to receive guidance throughout the complaint process, while enterprises can transform their handling of customer complaints.

ThisWay provides AI-powered recruitment and talent acquisition solutions that enable businesses, recruiters, and organizations to identify active and passive candidates, manage high-volume hiring, and streamline the sourcing process with an AI-driven candidate matching engine. The platform emphasizes data security through blockchain technology and interactive resumes, delivering matched and scored candidate lists quickly with no integration required. It seeks to improve efficiency, accuracy, and diversity in hiring to optimize ROI, and serves individuals and groups, including associations in education, arts, sports, and charities.

Concirrus operates a cloud platform that connects diverse data sources and devices, transforming businesses by managing and organizing information from connected products and machines. It offers custom solutions, pre-built applications in asset security, fleet management, smart energy, and patient monitoring, along with an incident monitoring center for theft recovery and securing high-value assets. Serving global clients across healthcare, security, mining, insurance, and other sectors, Concirrus empowers organizations to make data-driven decisions through its intelligence platform Quest.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

Abingdon Health is a UK-based company specializing in rapid diagnostic testing solutions. Established in 2008, it develops, manufactures, and markets lateral flow diagnostics worldwide, including COVID-19 neutralizing antibody tests, nucleic acid lateral flow immunoassays, and quantitative immunoglobulin free light chain measurements.

Econic Technologies Ltd. is a chemical technology company based in Macclesfield, United Kingdom, specializing in the development of innovative processes to convert carbon dioxide and epoxides into valuable polymers and polyurethanes. Founded in 2011, the company leverages catalyst chemistry to transform waste CO2 into commercially viable products, thereby reducing dependence on fossil fuels and providing environmental benefits. Econic's product offerings include polycarbonates and polycarbonate polyols, which are utilized in various applications such as mattresses, insulation, footwear, packaging, and construction materials. Additionally, the company produces glues and coatings for industrial uses. With patented catalyst technologies and a skilled team of scientists and engineers, Econic Technologies operates from a state-of-the-art facility at Alderley Park, focusing on turning scientific advancements into practical solutions for the plastics industry while addressing environmental challenges.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Featurespace is a technology company that develops Adaptive Behavioral Analytics and automated deep behavioral networks to prevent fraud and financial crime. Its ARIC platform provides real-time risk scoring and anomaly detection to monitor customer data across transactions and channels, automatically identifying risk, blocking new fraud attacks, and distinguishing genuine activity. The ARIC Risk Hub operates in real time and is used by more than 30 major global financial institutions to protect customers and revenue, spanning multiple countries. The company serves financial institutions and other sectors, including responsible gambling and churn protection, by analyzing streams of customer data to detect anomalies and prevent loss while minimizing disruption to legitimate customers.

Inflowmatix designs and implements electronic systems that provide water flow and system health analytics to water utilities worldwide. Its system optimizes water supply networks by monitoring fluid dynamics, improving leakage management, and extending the life of infrastructure.

Nexeon is an international developer and manufacturer of silicon-based anode materials for rechargeable lithium-ion batteries. The company focuses on silicon anodes to increase energy density, enabling lighter, smaller, and more cost-efficient batteries for a range of applications including electric vehicles and consumer electronics, as well as other sectors that require high-performance energy storage. Headquarters are in Oxfordshire, United Kingdom, and the company maintains operations in Japan, with a history dating back to 2006. By replacing traditional graphite anodes, Nexeon's materials aim to enhance battery performance while reducing overall carbon footprint.

Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

Founded in 2012, Aqdot specializes in innovative microencapsulation technology. Its patented one-step shrink-wrap approach combines emulsion technology and supramolecular chemistry to create smart microcapsules with customizable properties. This energy-efficient manufacturing process serves various industries, including household care, agrochemicals, and food sectors.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

SAM Labs Limited is an education technology company based in London, United Kingdom, established in 2014. It specializes in providing educators with resources that enhance teaching and learning experiences, particularly in the areas of coding and computational skills. The company offers a range of products including wireless electronic blocks, such as buttons, sensors, motors, and sliders, which can be connected via an intuitive software application called SAM Space. This platform allows students to visualize and code the blocks, enabling them to create interactive projects and engage in hands-on learning. SAM Labs also supplies curriculum-based lesson plans and in-classroom support to facilitate STEAM education, making coding accessible and fun. Its course kits and electronic products are available for purchase online, helping educators deliver comprehensive and engaging lessons across various subjects.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Silicon Microgravity is a Cambridge, United Kingdom based sensor technology company that develops microelectromechanical systems for oil and gas reservoir surveillance and other applications. Its gravity sensors deliver high-sensitivity gravity data and ultra-low-frequency seismic data from boreholes, enabling precise density measurements deep in reservoirs and real-time reservoir management. The technology originated as a Cambridge University spin-out, developed with support from BP and Innovate UK, and has broader uses in navigation and stabilization of intelligent systems across commercial, industrial, and military sectors. The company aims to improve efficiency, reduce costs, and support safety and environmental goals in hydrocarbon production.

Import.io Ltd, established in 2012, is a London-based Software as a Service (SaaS) company with an additional office in Los Gatos, California. It specializes in converting unstructured web data into structured, machine-readable formats. Import.io offers a suite of products, including automated web extraction, data monitoring, visualization, and analysis tools, as well as APIs for system integration. The company also provides solutions for competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 customers, delivering high-quality data from millions of web sources to fuel business insights and competitive advantage.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and headquartered in Abingdon-on-Thames, United Kingdom, the company focuses on providing key optical components for augmented reality applications. WaveOptics employs patented technology that utilizes waveguide holography and photonic crystals to create lightweight, high-performance displays. Their innovative designs feature a high field of view and full RGB color, allowing for an enriched user experience without the bulk typically associated with traditional augmented reality systems. The company has established strategic partnerships with leading firms such as Compal, Wistron, and Plessey to enhance its product offerings and market reach.

Telectic they provide AI capability to read the web and uncover hard to find B2B prospects, map emerging sectors, segment accounts and monitor companies on particular topics or signals. They have developed a crawler that understands the content from the web, reading company websites, news, social media, academic, official, and other sources.

Puridify Limited is a bioprocessing company based in Stevenage, United Kingdom, founded in 2013 by Tom Haywood, Oliver Hardick, and Iwan Roberts. The company specializes in developing advanced purification technologies for the manufacturing of industrial biomolecules. Its flagship product, FibroSelect, utilizes a unique nanofiber-based platform that enhances purification efficiency while addressing the limitations found in traditional packed bed chromatography systems. This innovative technology is designed to provide consistent purification performance across various scales, making it suitable for the purification of complex biotherapeutics, including gene therapies, viral vectors, and fusion proteins. By improving the efficiency and cost-effectiveness of biopharmaceutical production, Puridify aims to advance the industry and support the growing demand for high-quality biomolecule products.

Oxford Biotrans Limited is a biotechnology company based in Abingdon, United Kingdom, that specializes in the development and commercialization of high-value chemical compounds through enzyme technology. Founded in 2013, the company leverages patented cytochrome P450 enzyme technology to create natural-grade products from readily available feedstocks. Its flagship product, Nootkatone, is a grapefruit-flavored and scented compound derived from the biotransformation of Valencene, a citrus extract. Oxford Biotrans is focused on producing flavors and fragrances, while its technology also holds potential for applications in pheromones, pharmaceuticals, and other specialty chemicals. The company's innovations are grounded in over 15 years of research from the Department of Chemistry at the University of Oxford, emphasizing environmentally friendly practices that reduce chemical waste and energy consumption in production processes.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, established in 2011. The company specializes in developing innovative medicines aimed at treating hearing disorders, including hearing loss and tinnitus. In addition to its focus on auditory conditions, Autifony is also involved in drug discovery for central nervous system disorders, addressing challenges related to conditions such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By leveraging its platform, the company seeks to alleviate symptoms associated with these disorders and meet the unmet medical needs of patients.

Abingdon Health is a UK-based company specializing in rapid diagnostic testing solutions. Established in 2008, it develops, manufactures, and markets lateral flow diagnostics worldwide, including COVID-19 neutralizing antibody tests, nucleic acid lateral flow immunoassays, and quantitative immunoglobulin free light chain measurements.

Auspherix, established in 2013 and headquartered in Stevenage, UK, specializes in the discovery and development of organogold-based antibiotics to combat serious, hard-to-treat, or potentially life-threatening infections. The company aims to advance these novel antibiotics through pre-clinical and clinical development, potentially for broad-spectrum use, by seeking further investment or industry partnerships.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Yoyo Wallet, established in 2013 and headquartered in London, specializes in mobile payment solutions. It offers a user-friendly app enabling customers to make in-store purchases using their smartphones, processing over 150,000 monthly transactions. The platform combines payment and loyalty features, providing retailers with a marketing tool for in-store customer engagement and targeted rewards based on purchase history. Yoyo Wallet serves retailers, universities, and corporate locations across the United Kingdom.

Cortexica Vision Systems Ltd is a London-based company specializing in vision-based analytics and artificial intelligence solutions tailored for businesses. Founded in 2008, it focuses on helping industries such as retail, media, manufacturing, and pharmaceuticals leverage advanced computer vision technologies. Cortexica's offerings include visual search and image recognition services that enhance product discovery and personalize the shopping experience for e-commerce customers. The company's solutions also encompass automated retail operations, real-time monitoring for personal protection equipment compliance, and predictive video analytics to address various safety and security concerns. Additionally, Cortexica provides edge solutions for local processing and video analysis. With a foundation rooted in pioneering research from the Bioengineering Department of Imperial College London, Cortexica aims to deliver practical AI solutions that drive efficiency and return on investment for its clients, adapting its technology to meet specific industry needs.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Lontra Limited, established in 2004 and headquartered in Napton-on-the-Hill, UK, specializes in the development and manufacturing of innovative air and gas compressors. The company's flagship product, the Blade Compressor, is a patented, rotary device that offers up to a third more efficiency than traditional compressors, reducing energy consumption and enhancing reliability. Lontra serves a diverse range of industries, including automotive, wastewater treatment, manufacturing, and power generation, both in the UK and internationally. Backed by prominent industrial partners and supported by numerous grants and awards, Lontra continues to expand its product portfolio and explore new compressor applications.

Cortexica Vision Systems Ltd is a London-based company specializing in vision-based analytics and artificial intelligence solutions tailored for businesses. Founded in 2008, it focuses on helping industries such as retail, media, manufacturing, and pharmaceuticals leverage advanced computer vision technologies. Cortexica's offerings include visual search and image recognition services that enhance product discovery and personalize the shopping experience for e-commerce customers. The company's solutions also encompass automated retail operations, real-time monitoring for personal protection equipment compliance, and predictive video analytics to address various safety and security concerns. Additionally, Cortexica provides edge solutions for local processing and video analysis. With a foundation rooted in pioneering research from the Bioengineering Department of Imperial College London, Cortexica aims to deliver practical AI solutions that drive efficiency and return on investment for its clients, adapting its technology to meet specific industry needs.

Featurespace is a technology company that develops Adaptive Behavioral Analytics and automated deep behavioral networks to prevent fraud and financial crime. Its ARIC platform provides real-time risk scoring and anomaly detection to monitor customer data across transactions and channels, automatically identifying risk, blocking new fraud attacks, and distinguishing genuine activity. The ARIC Risk Hub operates in real time and is used by more than 30 major global financial institutions to protect customers and revenue, spanning multiple countries. The company serves financial institutions and other sectors, including responsible gambling and churn protection, by analyzing streams of customer data to detect anomalies and prevent loss while minimizing disruption to legitimate customers.

Puridify Limited is a bioprocessing company based in Stevenage, United Kingdom, founded in 2013 by Tom Haywood, Oliver Hardick, and Iwan Roberts. The company specializes in developing advanced purification technologies for the manufacturing of industrial biomolecules. Its flagship product, FibroSelect, utilizes a unique nanofiber-based platform that enhances purification efficiency while addressing the limitations found in traditional packed bed chromatography systems. This innovative technology is designed to provide consistent purification performance across various scales, making it suitable for the purification of complex biotherapeutics, including gene therapies, viral vectors, and fusion proteins. By improving the efficiency and cost-effectiveness of biopharmaceutical production, Puridify aims to advance the industry and support the growing demand for high-quality biomolecule products.

Yoyo Wallet, established in 2013 and headquartered in London, specializes in mobile payment solutions. It offers a user-friendly app enabling customers to make in-store purchases using their smartphones, processing over 150,000 monthly transactions. The platform combines payment and loyalty features, providing retailers with a marketing tool for in-store customer engagement and targeted rewards based on purchase history. Yoyo Wallet serves retailers, universities, and corporate locations across the United Kingdom.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

TopiVert Ltd. is a clinical-stage biotechnology company headquartered in London, United Kingdom, that specializes in developing narrow spectrum kinase inhibitors for the treatment of chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, TopiVert's primary focus is on creating non-systemic, locally acting medications that target conditions such as ulcerative colitis and dry eye syndrome. The company's lead program, TOP1288, is currently undergoing a Phase IIa proof of concept study for ulcerative colitis, while TOP1630, aimed at treating dry eye syndrome, is set to enter a Phase I/II study in the United States. By delivering targeted treatments at pharmacologically relevant concentrations, TopiVert aims to improve medical outcomes and enable faster commencement of effective therapies.

Econic Technologies Ltd. is a chemical technology company based in Macclesfield, United Kingdom, specializing in the development of innovative processes to convert carbon dioxide and epoxides into valuable polymers and polyurethanes. Founded in 2011, the company leverages catalyst chemistry to transform waste CO2 into commercially viable products, thereby reducing dependence on fossil fuels and providing environmental benefits. Econic's product offerings include polycarbonates and polycarbonate polyols, which are utilized in various applications such as mattresses, insulation, footwear, packaging, and construction materials. Additionally, the company produces glues and coatings for industrial uses. With patented catalyst technologies and a skilled team of scientists and engineers, Econic Technologies operates from a state-of-the-art facility at Alderley Park, focusing on turning scientific advancements into practical solutions for the plastics industry while addressing environmental challenges.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and headquartered in Redcar, United Kingdom, Plaxica develops innovative products such as Optipure, D Lactic Acid; Xylex, Lignin Free Sugars; and Versalac, Low Cost Lactic Acid technology. The company's offerings primarily include polylactic acid polymers, which are utilized across various industries, including food packaging, textiles, automotive, electronics, and household goods. By focusing on sustainable and renewable materials, Plaxica aims to contribute to the advancement of environmentally friendly solutions in the biopolymer sector.

Yoyo Wallet, established in 2013 and headquartered in London, specializes in mobile payment solutions. It offers a user-friendly app enabling customers to make in-store purchases using their smartphones, processing over 150,000 monthly transactions. The platform combines payment and loyalty features, providing retailers with a marketing tool for in-store customer engagement and targeted rewards based on purchase history. Yoyo Wallet serves retailers, universities, and corporate locations across the United Kingdom.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Cambridge Communication Systems Limited, founded in 2010 and based in Cambridge, United Kingdom, specializes in designing and developing advanced wireless backhaul solutions. The company focuses on self-organizing technologies that provide connectivity for various applications, including small cell networks, Wi-Fi, CCTV, smart cities, and enterprise access. Its flagship product, Metnet, is a self-organizing 5G microwave backhaul system that operates in the 24/26/28GHz frequency range. Cambridge Communication Systems aims to deliver gigabit connectivity through intelligent, self-optimizing, and self-healing mesh networks, which serve as a cost-effective extension of fiber infrastructure. This innovative approach allows network operators to create hybrid fiber-wireless networks, optimizing total cost of ownership across diverse environments, from urban to rural areas and residential to enterprise settings.

Impression Technologies Limited is a London-based company that specializes in the marketing and commercialization of Hot Form Quench (HFQ) technology, which facilitates the formation of aluminum panels into complex shapes. Established in 2012, the company provides a comprehensive service tailored to engineering needs, guiding clients from the initial concept through to production. Impression Technologies offers in-house prototyping and production capabilities at its facility in Coventry, UK, ensuring robust support for HFQ customers and partners. The company's expertise in HFQ technology enables it to empower clients to effectively transform their projects, leveraging advanced techniques in aluminum processing.

Semetric, founded in 2008 by Gregory Mead, Marie-Alicia Chang, and Matthew Jeffery, specializes in providing data-driven insights and analytics for the entertainment industry. The company's offerings include analytics, discovery, recommendations, and targeting services, aimed at enhancing business decisions within the sector. The leadership team features industry veterans such as Jameel Syed, the Chief Technical Officer with a background in life sciences data and business analytics, and Dr. Jeremy Silver, the Executive Chairman, who has held significant roles in software and media companies. Additionally, Daniel Savage, the Executive Vice President for Musicmetric North America, brings experience from various major record labels. Through its innovative solutions, Semetric supports clients in navigating and leveraging data for improved performance in entertainment.

Musicmetric provides analytics and trend forecasting tools tailored for the music industry, utilizing machine learning algorithms to assess online engagement and deliver actionable insights. The company's software is designed to analyze marketing performance, enhancing campaign efficiency and targeting accuracy. It offers predictive trend forecasting for artists, genres, and sales across various sectors, including mainstream labels, indie artists, and unsigned musicians. By processing vast amounts of raw text data daily, Musicmetric conducts data mining and classification analysis to fuel its software solutions. Additionally, the company is developing a suite of free widgets and an API to enable third parties to create applications leveraging its data. Its clientele includes record labels, A&R representatives, managers, promoters, and marketing agencies.

Acunu Analytics is a developer of database infrastructure and analytics software that specializes in low-latency, continuous analytics for big data. The company's platform enables real-time monitoring and control in various industries, such as manufacturing, telecommunications, media, and financial services, by powering dashboards and embedded applications for infrastructure monitoring and web analytics. At the core of Acunu's offerings is the Cassandra NoSQL database, and the company is actively involved in contributing innovations back to the Cassandra community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford Universities, Acunu is headquartered in London and has an additional office in California.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

Featurespace is a technology company that develops Adaptive Behavioral Analytics and automated deep behavioral networks to prevent fraud and financial crime. Its ARIC platform provides real-time risk scoring and anomaly detection to monitor customer data across transactions and channels, automatically identifying risk, blocking new fraud attacks, and distinguishing genuine activity. The ARIC Risk Hub operates in real time and is used by more than 30 major global financial institutions to protect customers and revenue, spanning multiple countries. The company serves financial institutions and other sectors, including responsible gambling and churn protection, by analyzing streams of customer data to detect anomalies and prevent loss while minimizing disruption to legitimate customers.

Abingdon Health is a UK-based company specializing in rapid diagnostic testing solutions. Established in 2008, it develops, manufactures, and markets lateral flow diagnostics worldwide, including COVID-19 neutralizing antibody tests, nucleic acid lateral flow immunoassays, and quantitative immunoglobulin free light chain measurements.

Econic Technologies Ltd. is a chemical technology company based in Macclesfield, United Kingdom, specializing in the development of innovative processes to convert carbon dioxide and epoxides into valuable polymers and polyurethanes. Founded in 2011, the company leverages catalyst chemistry to transform waste CO2 into commercially viable products, thereby reducing dependence on fossil fuels and providing environmental benefits. Econic's product offerings include polycarbonates and polycarbonate polyols, which are utilized in various applications such as mattresses, insulation, footwear, packaging, and construction materials. Additionally, the company produces glues and coatings for industrial uses. With patented catalyst technologies and a skilled team of scientists and engineers, Econic Technologies operates from a state-of-the-art facility at Alderley Park, focusing on turning scientific advancements into practical solutions for the plastics industry while addressing environmental challenges.

Cambridge Communication Systems Limited, founded in 2010 and based in Cambridge, United Kingdom, specializes in designing and developing advanced wireless backhaul solutions. The company focuses on self-organizing technologies that provide connectivity for various applications, including small cell networks, Wi-Fi, CCTV, smart cities, and enterprise access. Its flagship product, Metnet, is a self-organizing 5G microwave backhaul system that operates in the 24/26/28GHz frequency range. Cambridge Communication Systems aims to deliver gigabit connectivity through intelligent, self-optimizing, and self-healing mesh networks, which serve as a cost-effective extension of fiber infrastructure. This innovative approach allows network operators to create hybrid fiber-wireless networks, optimizing total cost of ownership across diverse environments, from urban to rural areas and residential to enterprise settings.

Epsilon-3 Bio Ltd. is a preclinical stage company with investment from Index Ventures, Novo Ventures and Imperial Innovations. The company is focused on the efficient development of first in class drug candidates stimulating safe removal of cellular debris. Such agents are expected to provide a useful treatment for a wide range of diseases including inflammation and autoimmunity, neurodegeneration, fibrosis and cancer.

TopiVert Ltd. is a clinical-stage biotechnology company headquartered in London, United Kingdom, that specializes in developing narrow spectrum kinase inhibitors for the treatment of chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, TopiVert's primary focus is on creating non-systemic, locally acting medications that target conditions such as ulcerative colitis and dry eye syndrome. The company's lead program, TOP1288, is currently undergoing a Phase IIa proof of concept study for ulcerative colitis, while TOP1630, aimed at treating dry eye syndrome, is set to enter a Phase I/II study in the United States. By delivering targeted treatments at pharmacologically relevant concentrations, TopiVert aims to improve medical outcomes and enable faster commencement of effective therapies.

Chirp is a technology company focused on simplifying connectivity through sound-based solutions. Its innovative machine-to-machine communications software allows devices equipped with loudspeakers or microphones to share data using inaudible sound waves. This technology facilitates seamless and scalable interconnection among millions of devices, enhancing user experiences and adding value to existing hardware. Chirp's commitment to research and development, supported by a world-class engineering team, positions it as a leader in the field of sound-based data exchange.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and headquartered in Redcar, United Kingdom, Plaxica develops innovative products such as Optipure, D Lactic Acid; Xylex, Lignin Free Sugars; and Versalac, Low Cost Lactic Acid technology. The company's offerings primarily include polylactic acid polymers, which are utilized across various industries, including food packaging, textiles, automotive, electronics, and household goods. By focusing on sustainable and renewable materials, Plaxica aims to contribute to the advancement of environmentally friendly solutions in the biopolymer sector.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, established in 2011. The company specializes in developing innovative medicines aimed at treating hearing disorders, including hearing loss and tinnitus. In addition to its focus on auditory conditions, Autifony is also involved in drug discovery for central nervous system disorders, addressing challenges related to conditions such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By leveraging its platform, the company seeks to alleviate symptoms associated with these disorders and meet the unmet medical needs of patients.

Nexeon is an international developer and manufacturer of silicon-based anode materials for rechargeable lithium-ion batteries. The company focuses on silicon anodes to increase energy density, enabling lighter, smaller, and more cost-efficient batteries for a range of applications including electric vehicles and consumer electronics, as well as other sectors that require high-performance energy storage. Headquarters are in Oxfordshire, United Kingdom, and the company maintains operations in Japan, with a history dating back to 2006. By replacing traditional graphite anodes, Nexeon's materials aim to enhance battery performance while reducing overall carbon footprint.

Stanmore Implants Worldwide Ltd., established in 1949, specializes in designing and manufacturing orthopedic implant systems for both juvenile and adult patients. The company focuses on orthopedic oncology, complex primary and revision cases in the upper limb, lower limb, and pelvis. Its product portfolio includes modular implant systems like METS, patient-specific implants, and extendible prostheses for limb-sparing and complex joint replacement. Stanmore Implants also offers a custom implant service and has a strategic partnership with WebOps LLC. The company, headquartered in Elstree, UK, operates as a subsidiary of Stryker Corporation.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Novacem Limited is a London-based company focused on developing a carbon-negative cement made from magnesium oxide and hydrated magnesium carbonates. This innovative approach aims to transform the cement industry, traditionally known for its significant carbon dioxide emissions, into a sector that can absorb CO2. By leveraging advanced materials science, Novacem seeks to provide sustainable alternatives to conventional cement, addressing environmental concerns while maintaining functionality in construction applications.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and headquartered in Redcar, United Kingdom, Plaxica develops innovative products such as Optipure, D Lactic Acid; Xylex, Lignin Free Sugars; and Versalac, Low Cost Lactic Acid technology. The company's offerings primarily include polylactic acid polymers, which are utilized across various industries, including food packaging, textiles, automotive, electronics, and household goods. By focusing on sustainable and renewable materials, Plaxica aims to contribute to the advancement of environmentally friendly solutions in the biopolymer sector.

Kuur Therapeutics Limited is a biopharmaceutical company focused on developing, manufacturing, and commercializing CAR-NKT cell immunotherapies for cancer treatment. The company is advancing a pipeline of immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics specializes in engineered off-the-shelf CAR-NKT cell therapies that leverage the natural biology of a specific subset of cytotoxic T cells known as natural killer T cells. This innovative approach aims to provide effective treatment options for a wide range of solid and hematological tumors. The company conducts clinical trials to demonstrate the efficacy of its CAR-NKT cell products, thereby striving to transform cancer care. Founded in 2005 and based in London, Kuur Therapeutics was previously known as Cell Medica Limited before its rebranding in February 2020.

Novacem Limited is a London-based company focused on developing a carbon-negative cement made from magnesium oxide and hydrated magnesium carbonates. This innovative approach aims to transform the cement industry, traditionally known for its significant carbon dioxide emissions, into a sector that can absorb CO2. By leveraging advanced materials science, Novacem seeks to provide sustainable alternatives to conventional cement, addressing environmental concerns while maintaining functionality in construction applications.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Evince Technology is a UK-based startup focused on the development of innovative electron devices utilizing synthetic diamonds. The company aims to revolutionize the high-frequency electronics industry by introducing a new type of solid-state switch that serves as a foundational element for effective electrical energy control. Its products are designed for various applications, including metrology, healthcare, communications, and advanced manufacturing. By harnessing the superior thermal and electronic properties of diamonds, Evince Technology provides manufacturers and developers with the potential for enhanced performance through its licensed thermionic valve technology.

Spiral Gateway is a fabless semiconductor chip vendor with products that are designed to enhance flexibility and performance in the Image Signal Processing (ISP) market. The company was formed in 2004 as a spinout from the University of Edinburgh and holds exclusive rights to RICA (Reconfigurable Instruction Cell Architecture), a novel processing architecture and associated tool chain. This technology has the potential to achieve cost & performance points for existing signal processing functions, directly comparable with fixed function custom hardware, whilst offering the significant additional benefit of high degrees of flexibility through software programmability.

Circassia Group Plc is a specialty pharmaceutical company based in Oxford, United Kingdom, that specializes in the development and commercialization of respiratory products. The company operates through three main segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. Circassia markets NIOX and NIOX VERO, products designed for asthma diagnosis and management, and offers Tudorza and Duaklir for the treatment of COPD. The latter is a fixed-dose combination inhaler that delivers medication for COPD maintenance. Additionally, Circassia is advancing LungFit, a portable system that generates precise amounts of nitric oxide for therapeutic use. The company sells its products directly to specialists in several countries, including the United States, United Kingdom, China, Italy, and Germany, as well as through international partners. Circassia has a collaboration with AstraZeneca for the promotion of Tudorza and Duaklir, along with U.S. and Chinese commercial rights to LungFit. Founded in 2006, Circassia Group Plc was formerly known as Circassia Pharmaceuticals plc until its name change in May 2020.

Molecular Vision is an optical detection company based in London, United Kingdom, founded in 2001. The company specializes in developing a health technology platform that integrates low-cost organic light-emitting diodes and organic photodetectors with analytical devices. This innovative approach enables the creation of instrument-free, disposable point-of-care (PoC) diagnostic devices capable of measuring multiple parameters from a single sample, yielding both quantitative and qualitative data. Beyond medical diagnostics, Molecular Vision's portable analytical devices have applications in various fields, including veterinary testing, food and plant analysis, environmental monitoring, and homeland security.

NanoBioDesign Limited (NBD) was formed in 2001 and is a spinout company from Imperial College London. The company has acquired the exclusive rights to four patents emanating from the research of Professor Gianfranco Gilardi and his group. Professor Gilardi has been active in the field of biological sensor research for 10 years, focussing upon human and bacterial P450’s.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Southside Thermal Sciences is developing an integrated system for turbine engines consisting of thermal barrier coatings (TBC) and the instruments required to make use of them. The TBC technology, which is patent-protected in the USA and Europe, has been developed for use on high temperature turbine blades, as used in gas-turbine power generators and aircraft engines. When illuminated by UV light the coatings provide accurate temperature readings leading to savings in operating costs and greater efficiency.

InforSense, Ltd. is a provider of enterprise business intelligence and reporting software, specializing in high-performance computing and large-scale data mining solutions. Founded in 1999 and based in London, the company offers a range of products, including the InforSense Platform, which enables organizations to integrate, automate, and visualize diverse data sources and analysis processes for predictive insights. Its product suite features advanced analytics tools, such as VisualSense and TextSense, along with Life Science Applications like ClinicalSense and GenSense, which support clinical research and data analysis in the life sciences sector. InforSense also delivers business intelligence solutions for various industries, including pharmaceuticals, biotechnology, healthcare, and financial services. Additionally, the company provides consulting, training, and workshop services to enhance user engagement and application of its solutions. With operations in the United Kingdom, the United States, Germany, and Japan, InforSense is positioned to serve a global clientele across multiple sectors.

Lontra Limited, established in 2004 and headquartered in Napton-on-the-Hill, UK, specializes in the development and manufacturing of innovative air and gas compressors. The company's flagship product, the Blade Compressor, is a patented, rotary device that offers up to a third more efficiency than traditional compressors, reducing energy consumption and enhancing reliability. Lontra serves a diverse range of industries, including automotive, wastewater treatment, manufacturing, and power generation, both in the UK and internationally. Backed by prominent industrial partners and supported by numerous grants and awards, Lontra continues to expand its product portfolio and explore new compressor applications.

Midaz Lasers manufactures high power diode-pumped solid state laser products for micromachining applications.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Vivant is a digital media and technology platform that focuses on fashion and lifestyle content, offering users trend reports, shopping guides, and news related to celebrity styles. Founded in 2008 by a team that includes Ari S. Goldberg and Maverick Carter, the platform serves as a space for women to express their individual style and connects them with brands to enhance advertising effectiveness. By fostering engagement among users who prioritize their appearance and well-being, Vivant aims to create a supportive community that celebrates personal style.

Pointshare is a national leader in connecting local healthcare communities with secure, online business services that enhance communication, create efficiencies, and improve the delivery of care. Pointshare is the only company that has developed the technology, infrastructure, and hands-on service to create a proven, practical solution for automating the day-to-day business transactions of healthcare.